History and Global Brand
Since 1878, we have been harnessing the full potential of science to treat challenging human diseases. Our discoveries have led to new treatment options that have improved the lives of patients worldwide. Throughout our history, we have remained true to our founding principle — to supply the best possible medicines to protect the health and well-being of the patients we serve.
1878 – The Founding
1886 – Acquiring Western Medicines
1910 – Construction of First Manufacturing Plant
Early 1910s – First Steps in Product Development & Fighting Infectious Disease
1950s – Global Contributions and First Partnerships
Beginning with our own research and development in infectious disease, we introduced Sinomin, a sulfonamide antibiotic, in 1959 and soon out-licensed it to Roche. The antibiotic circulated worldwide, becoming an instrumental tool in the fight against infectious diseases. This period also marked the beginning of our collaboration with other global pharmaceutical companies, including Eli Lilly and Company.
1980s – Growth and Specialization
2001 – United States Expansion
2008 – Acquisitions and Further Success
2010s – Drug Discovery and Continued Growth
2020s – Advancing Science and Expanding Global Presence
A Legacy in Infectious Disease
Since 1953, Shionogi has been a leader in infectious disease discovery and commercialization.
1953ERYTHROMYCIN – was licensed in Japan
1959SULFAMETHOXAZOLE – a sulfa antibiotic used to treat bacterial infections
1970CEPHALEXIN – a first-generation cephalosporin
1981VANCOMYCIN – a Gram-positive anti-MRSA
1982LATAMOXEF/MOXALACTAM – the first of two globally approved oxacephems CEFACLOR – a second-generation cephalosporin
1984CEFAMANDOLE – a second-generation cephalosporin
1988FLOMOXEF – the second of two globally approved oxacephems
1992CEFTIBUTEN – a third-generation oral cephalosporin antibiotic
1993CEFPIROME – a fourth-generation cephalosporin
1997CEFCAPENE – a third-generation oral cephalosporin antibiotic
2005DORIPENEM – a carbapenem antibiotic
2010PERAMIVIR – an antiviral for influenza
2013DOLUTEGRAVIR – an HIV integrase inhibitor
2018BALOXAVIR MARBOXIL – antiviral drug
2019CEFIDEROCOL – cephalosporin for certain Gram-negative infections
2022ENSITRELVIR – an investigational oral antiviral for COVID-19
2023XERUBORBACTAM – an investigational β-lactamase inhibitor
KeyCommercialized by Shionogi Discovered and commercialized by Shionogi
Our Global Brand
Our corporate logo is derived from the “fundoh,” a stylized image of a balance weight traditionally used to weigh medicine on a scale. The fundoh also symbolizes “accuracy,” “honesty,” and “trust” and represents precision and our commitment to quality.
Capability and Vision, Unified
"Trust" and "Accuracy."
Dynamic expression and unity.
Designed to give a sense of trust and security.